Paclitaxel Serum Concentrations Linked to Severity of Neuropathy in Breast Cancer Patients

Video

This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, discusses a 60-patient study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.

Henry was one of the coauthors of the study (abstract P6-11-03), which was presented during a poster session at the 2017 San Antonio Breast Cancer Symposium (SABCS).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.